CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. High bargaining power of suppliers
3.3.2. Moderate threat of new entrants
3.3.3. High threat of substitutes
3.3.4. Moderate intensity of rivalry
3.3.5. Moderate bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increased Drug Development Activities
3.4.1.2. Patient Compliance offered by pharmaceutical suspensions
3.4.1.3. Availability of generic pharmaceutical suspensions
3.4.2. Restraints
3.4.2.1. Limited drug compatibility
3.4.3. Opportunities
3.4.3.1. Growing initiatives for market expansion
CHAPTER 4: PHARMACEUTICAL SUSPENSION MARKET, BY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Oral
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Parenteral
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Others
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
CHAPTER 5: PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Infectious Diseases
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Cancer
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Gastrointestinal
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Neurological
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
5.6. Others
5.6.1. Key market trends, growth factors and opportunities
5.6.2. Market size and forecast, by region
5.6.3. Market share analysis by country
CHAPTER 6: PHARMACEUTICAL SUSPENSION MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospitals and Clinics
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Home Care Settings
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Others
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL
7.1. Overview
7.1.1. Market size and forecast
7.2. Hospital Pharmacies
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by region
7.2.3. Market share analysis by country
7.3. Drug Store and Retail Pharmacies
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by region
7.3.3. Market share analysis by country
7.4. Online Providers
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by region
7.4.3. Market share analysis by country
CHAPTER 8: PHARMACEUTICAL SUSPENSION MARKET, BY REGION
8.1. Overview
8.1.1. Market size and forecast By Region
8.2. North America
8.2.1. Key market trends, growth factors and opportunities
8.2.2. Market size and forecast, by Type
8.2.3. Market size and forecast, by Indication
8.2.4. Market size and forecast, by End User
8.2.5. Market size and forecast, by Distribution Channel
8.2.6. Market size and forecast, by country
8.2.6.1. U.S.
8.2.6.1.1. Market size and forecast, by Type
8.2.6.1.2. Market size and forecast, by Indication
8.2.6.1.3. Market size and forecast, by End User
8.2.6.1.4. Market size and forecast, by Distribution Channel
8.2.6.2. Canada
8.2.6.2.1. Market size and forecast, by Type
8.2.6.2.2. Market size and forecast, by Indication
8.2.6.2.3. Market size and forecast, by End User
8.2.6.2.4. Market size and forecast, by Distribution Channel
8.2.6.3. Mexico
8.2.6.3.1. Market size and forecast, by Type
8.2.6.3.2. Market size and forecast, by Indication
8.2.6.3.3. Market size and forecast, by End User
8.2.6.3.4. Market size and forecast, by Distribution Channel
8.3. Europe
8.3.1. Key market trends, growth factors and opportunities
8.3.2. Market size and forecast, by Type
8.3.3. Market size and forecast, by Indication
8.3.4. Market size and forecast, by End User
8.3.5. Market size and forecast, by Distribution Channel
8.3.6. Market size and forecast, by country
8.3.6.1. Germany
8.3.6.1.1. Market size and forecast, by Type
8.3.6.1.2. Market size and forecast, by Indication
8.3.6.1.3. Market size and forecast, by End User
8.3.6.1.4. Market size and forecast, by Distribution Channel
8.3.6.2. France
8.3.6.2.1. Market size and forecast, by Type
8.3.6.2.2. Market size and forecast, by Indication
8.3.6.2.3. Market size and forecast, by End User
8.3.6.2.4. Market size and forecast, by Distribution Channel
8.3.6.3. UK
8.3.6.3.1. Market size and forecast, by Type
8.3.6.3.2. Market size and forecast, by Indication
8.3.6.3.3. Market size and forecast, by End User
8.3.6.3.4. Market size and forecast, by Distribution Channel
8.3.6.4. Italy
8.3.6.4.1. Market size and forecast, by Type
8.3.6.4.2. Market size and forecast, by Indication
8.3.6.4.3. Market size and forecast, by End User
8.3.6.4.4. Market size and forecast, by Distribution Channel
8.3.6.5. Spain
8.3.6.5.1. Market size and forecast, by Type
8.3.6.5.2. Market size and forecast, by Indication
8.3.6.5.3. Market size and forecast, by End User
8.3.6.5.4. Market size and forecast, by Distribution Channel
8.3.6.6. Rest of Europe
8.3.6.6.1. Market size and forecast, by Type
8.3.6.6.2. Market size and forecast, by Indication
8.3.6.6.3. Market size and forecast, by End User
8.3.6.6.4. Market size and forecast, by Distribution Channel
8.4. Asia-Pacific
8.4.1. Key market trends, growth factors and opportunities
8.4.2. Market size and forecast, by Type
8.4.3. Market size and forecast, by Indication
8.4.4. Market size and forecast, by End User
8.4.5. Market size and forecast, by Distribution Channel
8.4.6. Market size and forecast, by country
8.4.6.1. Japan
8.4.6.1.1. Market size and forecast, by Type
8.4.6.1.2. Market size and forecast, by Indication
8.4.6.1.3. Market size and forecast, by End User
8.4.6.1.4. Market size and forecast, by Distribution Channel
8.4.6.2. China
8.4.6.2.1. Market size and forecast, by Type
8.4.6.2.2. Market size and forecast, by Indication
8.4.6.2.3. Market size and forecast, by End User
8.4.6.2.4. Market size and forecast, by Distribution Channel
8.4.6.3. India
8.4.6.3.1. Market size and forecast, by Type
8.4.6.3.2. Market size and forecast, by Indication
8.4.6.3.3. Market size and forecast, by End User
8.4.6.3.4. Market size and forecast, by Distribution Channel
8.4.6.4. Australia
8.4.6.4.1. Market size and forecast, by Type
8.4.6.4.2. Market size and forecast, by Indication
8.4.6.4.3. Market size and forecast, by End User
8.4.6.4.4. Market size and forecast, by Distribution Channel
8.4.6.5. South Korea
8.4.6.5.1. Market size and forecast, by Type
8.4.6.5.2. Market size and forecast, by Indication
8.4.6.5.3. Market size and forecast, by End User
8.4.6.5.4. Market size and forecast, by Distribution Channel
8.4.6.6. Rest of Asia-Pacific
8.4.6.6.1. Market size and forecast, by Type
8.4.6.6.2. Market size and forecast, by Indication
8.4.6.6.3. Market size and forecast, by End User
8.4.6.6.4. Market size and forecast, by Distribution Channel
8.5. LAMEA
8.5.1. Key market trends, growth factors and opportunities
8.5.2. Market size and forecast, by Type
8.5.3. Market size and forecast, by Indication
8.5.4. Market size and forecast, by End User
8.5.5. Market size and forecast, by Distribution Channel
8.5.6. Market size and forecast, by country
8.5.6.1. Brazil
8.5.6.1.1. Market size and forecast, by Type
8.5.6.1.2. Market size and forecast, by Indication
8.5.6.1.3. Market size and forecast, by End User
8.5.6.1.4. Market size and forecast, by Distribution Channel
8.5.6.2. Saudi Arabia
8.5.6.2.1. Market size and forecast, by Type
8.5.6.2.2. Market size and forecast, by Indication
8.5.6.2.3. Market size and forecast, by End User
8.5.6.2.4. Market size and forecast, by Distribution Channel
8.5.6.3. South Africa
8.5.6.3.1. Market size and forecast, by Type
8.5.6.3.2. Market size and forecast, by Indication
8.5.6.3.3. Market size and forecast, by End User
8.5.6.3.4. Market size and forecast, by Distribution Channel
8.5.6.4. Rest of LAMEA
8.5.6.4.1. Market size and forecast, by Type
8.5.6.4.2. Market size and forecast, by Indication
8.5.6.4.3. Market size and forecast, by End User
8.5.6.4.4. Market size and forecast, by Distribution Channel
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product mapping of top 10 player
9.4. Competitive dashboard
9.5. Competitive heatmap
9.6. Top player positioning, 2022
CHAPTER 10: COMPANY PROFILES
10.1. Pfizer Inc.
10.1.1. Company overview
10.1.2. Key executives
10.1.3. Company snapshot
10.1.4. Operating business segments
10.1.5. Product portfolio
10.1.6. Business performance
10.2. Merck & Co., Inc.
10.2.1. Company overview
10.2.2. Key executives
10.2.3. Company snapshot
10.2.4. Operating business segments
10.2.5. Product portfolio
10.2.6. Business performance
10.2.7. Key strategic moves and developments
10.3. AstraZeneca plc
10.3.1. Company overview
10.3.2. Key executives
10.3.3. Company snapshot
10.3.4. Operating business segments
10.3.5. Product portfolio
10.3.6. Business performance
10.4. Eli Lilly and Company.
10.4.1. Company overview
10.4.2. Key executives
10.4.3. Company snapshot
10.4.4. Operating business segments
10.4.5. Product portfolio
10.4.6. Business performance
10.5. Bayer AG
10.5.1. Company overview
10.5.2. Key executives
10.5.3. Company snapshot
10.5.4. Operating business segments
10.5.5. Product portfolio
10.5.6. Business performance
10.6. Sanofi
10.6.1. Company overview
10.6.2. Key executives
10.6.3. Company snapshot
10.6.4. Operating business segments
10.6.5. Product portfolio
10.6.6. Business performance
10.7. Lupin
10.7.1. Company overview
10.7.2. Key executives
10.7.3. Company snapshot
10.7.4. Operating business segments
10.7.5. Product portfolio
10.7.6. Business performance
10.7.7. Key strategic moves and developments
10.8. Glenmark Pharmaceuticals Limited
10.8.1. Company overview
10.8.2. Key executives
10.8.3. Company snapshot
10.8.4. Operating business segments
10.8.5. Product portfolio
10.8.6. Business performance
10.8.7. Key strategic moves and developments
10.9. Novartis AG
10.9.1. Company overview
10.9.2. Key executives
10.9.3. Company snapshot
10.9.4. Operating business segments
10.9.5. Product portfolio
10.9.6. Business performance
10.10. Teva Pharmaceutical Industries Limited
10.10.1. Company overview
10.10.2. Key executives
10.10.3. Company snapshot
10.10.4. Operating business segments
10.10.5. Product portfolio
10.10.6. Business performance
10.10.7. Key strategic moves and developments
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
